liranaftate

Zefnart (liranaftate) is a topical thiocarbamate antifungal agent developed for the treatment of superficial fungal skin infections. It functions by selectively inhibiting the fungal enzyme squalene epoxidase, which is a critical component of the ergosterol biosynthesis pathway. This inhibition leads to a depletion of ergosterol, an essential sterol for fungal cell membrane integrity, and a concomitant accumulation of squalene, which is toxic to the fungal cell. The resulting disruption of the cell membrane leads to fungicidal activity. Approved in Japan in August 2000, Zefnart is available as a 2% cream or solution and is primarily indicated for the treatment of tinea pedis (athlete's foot), tinea corporis (ringworm), and tinea cruris (jock itch).

Brand names

Zefnart

Other names

liranaftate